What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes? Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial

被引:177
作者
Bangalore, Sripal [2 ]
Qin, Jie
Sloan, Sarah
Murphy, Sabina A.
Cannon, Christopher P. [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, TIMI Study Grp,Div Cardiovasc Med, Boston, MA 02115 USA
[2] NYU, Sch Med, New York, NY USA
关键词
blood pressure; hypertension; prognosis; acute coronary syndrome; J-CURVE; HYPERTENSIVE PATIENTS; HEART-DISEASE; REDUCTION; DEATH; PREVENTION; MANAGEMENT; MORTALITY; POINT; RISK;
D O I
10.1161/CIRCULATIONAHA.109.905687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes. Methods and Results-We evaluated 4162 patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial (acute coronary syndrome patients randomized to pravastatin 40 mg versus atorvastatin 80 mg). The average follow-up BP (systolic and diastolic) was categorized into 10-mm Hg increments. The primary outcome was a composite of death due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal myocardial infarction, or revascularization. The relationship between BP (systolic or diastolic) followed a J- or U-shaped curve association with primary, secondary, and individual outcomes, with increased events rates at both low and high BP values, both unadjusted and after adjustment for baseline variables, baseline C-reactive protein, and on-treatment average levels of low-density lipoprotein cholesterol. A nonlinear Cox proportional hazards model showed a nadir of 136/85 mm Hg (range 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic) at which the incidence of primary outcome was lowest. The curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg. Conclusions-After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially <110/70 mm Hg) may be dangerous.
引用
收藏
页码:2142 / 2151
页数:10
相关论文
共 30 条
  • [21] Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure the CAMELOT study: A randomized controlled trial
    Nissen, SE
    Tuzcu, EM
    Libby, P
    Thompson, PD
    Ghali, M
    Garza, D
    Berman, L
    Shi, H
    Buebendorf, E
    Topol, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18): : 2217 - 2226
  • [22] Diastolic blood pressure and mortality in the elderly with cardiovascular disease
    Protogerou, Athanase D.
    Safar, Michel E.
    Iaria, Pierre
    Safar, Helene
    Le Dudal, Katia
    Filipovsky, Jan
    Henry, Olivier
    Ducimetiere, Pierre
    Blacher, Jacques
    [J]. HYPERTENSION, 2007, 50 (01) : 172 - 180
  • [23] Treatment of hypertension in the prevention and management of ischemic heart disease - A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention
    Rosendorff, Clive
    Black, Henry R.
    Cannon, Christopher P.
    Gersh, Bernard J.
    Gore, Joel
    Izzo, Joseph L., Jr.
    Kaplan, Norman M.
    O'Connor, Christopher M.
    O'Gara, Patrick T.
    Oparil, Suzanne
    [J]. CIRCULATION, 2007, 115 (21) : 2761 - 2788
  • [24] Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
    Sleight, Peter
    Redon, Josep
    Verdecchia, Paolo
    Mancia, Giuseppe
    Gao, Peggy
    Fagard, Robert
    Schumacher, Helmut
    Weber, Michael
    Boehm, Michael
    Williams, Bryan
    Pogue, Janice
    Koon, Teo
    Yusuf, Salim
    [J]. JOURNAL OF HYPERTENSION, 2009, 27 (07) : 1360 - 1369
  • [25] Potential adverse effects of blood pressure lowering - J-curve revisited
    Staessen, JA
    [J]. LANCET, 1996, 348 (9029) : 696 - 697
  • [26] STEWART IMG, 1979, LANCET, V1, P861
  • [27] Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial
    Verdecchia, Paolo
    Staessen, Jan A.
    Angeli, Fabio
    de Simone, Giovanni
    Achilli, Augusto
    Ganau, Antonello
    Mureddu, Gianfrancesco
    Pede, Sergio
    Maggioni, Aldo P.
    Lucci, Donato
    Reboldi, Gianpaolo
    [J]. LANCET, 2009, 374 (9689) : 525 - 533
  • [28] WALLER PC, 1988, J HUM HYPERTENS, V2, P7
  • [29] DO NO HARM - ANTIHYPERTENSIVE THERAPY AND THE J CURVE
    WEINBERGER, MH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (03) : 473 - 476
  • [30] British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
    Williams, B
    Poulter, NR
    Brown, MJ
    Davis, M
    McInnes, GT
    Potter, MF
    Sever, PS
    Thom, SM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7440): : 634 - 640